Appointment dossier — Large-Cell Neuroendocrine Carcinoma
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Large-Cell Neuroendocrine Carcinoma
No studies or cited compounds on file for this cancer yet.
Open recruiting trials (18)
- NCT06176989 · Phase 2 — Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors (United States)
- NCT06418087 · Phase 2 — Durvalumab With Carboplatin and Etoposide Chemotherapy in Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC) (Italy)
- NCT07410494 · Phase 1 / Phase 2 — Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors (China)
- NCT07278479 · Phase 1 / Phase 2 — Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors (United States)
- NCT06424665 · Phase 1 — A Study of FZ-AD005 in Patients With Advanced Solid Tumors (China)
- NCT06022029 · Phase 1 — A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. (United States)
- NCT07006727 · Phase 1 — Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors (United States)
- NCT06937905 · Phase 3 — Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs) (France)
- NCT06406465 · Phase 2 — A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity (United States)
- NCT06393816 · Phase 2 — FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum (France)
- NCT06814496 · Phase 1 / Phase 2 — Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors (United States)
- NCT06228066 · Phase 2 — Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER) (United States)
- NCT05652686 · Phase 1 / Phase 2 — A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) (United States)
- NCT03866382 · Phase 2 — Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors (United States)
- NCT07080242 · Phase 1 — Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors (United States)
- NCT06717243 — Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS) (United States)
- NCT04907643 — Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes (United States)
- NCT04723095 — Establishing a Tumor Registry for Patients With Neuroendocrine Carcinoma of the Cervix (United States)
Most-relevant first: trials that name Large-Cell Neuroendocrine Carcinoma, then broader trials you may still qualify for. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
Questions to ask your oncologist
- Of the open trials I found (for example NCT06176989), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?
- What will treatment cost, and is financial assistance available?
- Should my tumor tissue be stored (biobanked) for future testing or trials?